Facility: HOPE Clinical Trials Facility, Leicester Royal Infirmary
Welcome,         Profile    Billing    Logout  
 5 Trials 
11 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Fennell, Dean A
CONFIRM, NCT03063450 / 2016-003111-35: CheckpOiNt Blockade For Inhibition of Relapsed Mesothelioma

Active, not recruiting
3
332
Europe
Nivolumab, Opdivo, Placebo
University of Southampton, Bristol-Myers Squibb
Mesothelioma
02/23
02/23
DENIM, NCT03610360 / 2017-001774-41: DENdritic Cell Immunotherapy for Mesothelioma

Completed
2/3
176
Europe
MesoPher
Amphera BV, TMC Pharma
Mesothelioma
06/22
06/22
MiST, NCT03654833 / 2017-003353-41: Mesothelioma Stratified Therapy () : A Multi-drug Phase II Trial in Malignant Mesothelioma

Active, not recruiting
2
186
Europe
Rucaparib, CO-338, Abemaciclib, LY2835219, pembrolizumab & bemcentinib, Keytruda; BGB324, Atezolizumab & Bevacizumab, MPDL3280A; Avastin, Dostarlimab and Niraparib, Zejula
University of Leicester, British Lung Foundation, Clovis Oncology, Inc., Eli Lilly and Company, Merck Sharp & Dohme LLC, BerGenBio ASA, Roche Pharma AG, University Hospitals, Leicester, The Christie NHS Foundation Trust, GlaxoSmithKline
Mesothelioma, Malignant
10/23
10/23
NERO, NCT05455424: Niraparib Efficacy in Patient With Unresectable Mesothelioma

Active, not recruiting
2
88
Europe
Niraparib Oral Product, Zejula, Active Symptom Control
University Hospital Southampton NHS Foundation Trust, University of Southampton, British Lung Foundation
Mesothelioma, Malignant
12/24
12/24
MITOPE, NCT05278975: Study of RSO-021 in Patients With Malignant Pleural Effusion Due to Advanced/Metastatic Solid Tumors Including Mesothelioma

Recruiting
1/2
186
Europe
RSO-021, Thiostrepton
RS Oncology LLC
Malignant Pleural Effusion, Malignant Pleural Mesothelioma, Mesothelioma, Mesotheliomas Pleural, Mesothelioma; Lung, Pleural Effusion, Malignant
04/25
04/25
NCT05228015: Oral TEAD Inhibitor Targeting the Hippo Pathway in Subjects with Advanced Solid Tumors

Terminated
1
67
Europe, US, RoW
IK-930, Osimertinib
Ikena Oncology
Solid Tumors, Adult, Solid Tumor, Malignant Pleural Mesothelioma (MPM), Epithelioid Hemangioendothelioma (EHE), NF2 Deficient Mesothelioma, Other NF2 Deficient Solid Tumors and Solid Tumors with YAP1/TAZ Fusion Genes, NF2 Deficiency, YAP1 or TAZ Gene Fusions
08/24
09/24
TRACERx, NCT01888601: TRAcking Non-small Cell Lung Cancer Evolution Through Therapy (Rx)

Active, not recruiting
N/A
814
Europe
University College, London, Cancer Research UK
Non-small Cell Lung Cancer
12/26
12/26
Blyth, Kevin
MITOPE, NCT05278975: Study of RSO-021 in Patients With Malignant Pleural Effusion Due to Advanced/Metastatic Solid Tumors Including Mesothelioma

Recruiting
1/2
186
Europe
RSO-021, Thiostrepton
RS Oncology LLC
Malignant Pleural Effusion, Malignant Pleural Mesothelioma, Mesothelioma, Mesotheliomas Pleural, Mesothelioma; Lung, Pleural Effusion, Malignant
04/25
04/25
TRACERx, NCT01888601: TRAcking Non-small Cell Lung Cancer Evolution Through Therapy (Rx)

Active, not recruiting
N/A
814
Europe
University College, London, Cancer Research UK
Non-small Cell Lung Cancer
12/26
12/26
Scotland, Molly
MiST, NCT03654833 / 2017-003353-41: Mesothelioma Stratified Therapy () : A Multi-drug Phase II Trial in Malignant Mesothelioma

Active, not recruiting
2
186
Europe
Rucaparib, CO-338, Abemaciclib, LY2835219, pembrolizumab & bemcentinib, Keytruda; BGB324, Atezolizumab & Bevacizumab, MPDL3280A; Avastin, Dostarlimab and Niraparib, Zejula
University of Leicester, British Lung Foundation, Clovis Oncology, Inc., Eli Lilly and Company, Merck Sharp & Dohme LLC, BerGenBio ASA, Roche Pharma AG, University Hospitals, Leicester, The Christie NHS Foundation Trust, GlaxoSmithKline
Mesothelioma, Malignant
10/23
10/23
MITOPE, NCT05278975: Study of RSO-021 in Patients With Malignant Pleural Effusion Due to Advanced/Metastatic Solid Tumors Including Mesothelioma

Recruiting
1/2
186
Europe
RSO-021, Thiostrepton
RS Oncology LLC
Malignant Pleural Effusion, Malignant Pleural Mesothelioma, Mesothelioma, Mesotheliomas Pleural, Mesothelioma; Lung, Pleural Effusion, Malignant
04/25
04/25
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Fennell, Dean A
CONFIRM, NCT03063450 / 2016-003111-35: CheckpOiNt Blockade For Inhibition of Relapsed Mesothelioma

Active, not recruiting
3
332
Europe
Nivolumab, Opdivo, Placebo
University of Southampton, Bristol-Myers Squibb
Mesothelioma
02/23
02/23
DENIM, NCT03610360 / 2017-001774-41: DENdritic Cell Immunotherapy for Mesothelioma

Completed
2/3
176
Europe
MesoPher
Amphera BV, TMC Pharma
Mesothelioma
06/22
06/22
MiST, NCT03654833 / 2017-003353-41: Mesothelioma Stratified Therapy () : A Multi-drug Phase II Trial in Malignant Mesothelioma

Active, not recruiting
2
186
Europe
Rucaparib, CO-338, Abemaciclib, LY2835219, pembrolizumab & bemcentinib, Keytruda; BGB324, Atezolizumab & Bevacizumab, MPDL3280A; Avastin, Dostarlimab and Niraparib, Zejula
University of Leicester, British Lung Foundation, Clovis Oncology, Inc., Eli Lilly and Company, Merck Sharp & Dohme LLC, BerGenBio ASA, Roche Pharma AG, University Hospitals, Leicester, The Christie NHS Foundation Trust, GlaxoSmithKline
Mesothelioma, Malignant
10/23
10/23
NERO, NCT05455424: Niraparib Efficacy in Patient With Unresectable Mesothelioma

Active, not recruiting
2
88
Europe
Niraparib Oral Product, Zejula, Active Symptom Control
University Hospital Southampton NHS Foundation Trust, University of Southampton, British Lung Foundation
Mesothelioma, Malignant
12/24
12/24
MITOPE, NCT05278975: Study of RSO-021 in Patients With Malignant Pleural Effusion Due to Advanced/Metastatic Solid Tumors Including Mesothelioma

Recruiting
1/2
186
Europe
RSO-021, Thiostrepton
RS Oncology LLC
Malignant Pleural Effusion, Malignant Pleural Mesothelioma, Mesothelioma, Mesotheliomas Pleural, Mesothelioma; Lung, Pleural Effusion, Malignant
04/25
04/25
NCT05228015: Oral TEAD Inhibitor Targeting the Hippo Pathway in Subjects with Advanced Solid Tumors

Terminated
1
67
Europe, US, RoW
IK-930, Osimertinib
Ikena Oncology
Solid Tumors, Adult, Solid Tumor, Malignant Pleural Mesothelioma (MPM), Epithelioid Hemangioendothelioma (EHE), NF2 Deficient Mesothelioma, Other NF2 Deficient Solid Tumors and Solid Tumors with YAP1/TAZ Fusion Genes, NF2 Deficiency, YAP1 or TAZ Gene Fusions
08/24
09/24
TRACERx, NCT01888601: TRAcking Non-small Cell Lung Cancer Evolution Through Therapy (Rx)

Active, not recruiting
N/A
814
Europe
University College, London, Cancer Research UK
Non-small Cell Lung Cancer
12/26
12/26
Blyth, Kevin
MITOPE, NCT05278975: Study of RSO-021 in Patients With Malignant Pleural Effusion Due to Advanced/Metastatic Solid Tumors Including Mesothelioma

Recruiting
1/2
186
Europe
RSO-021, Thiostrepton
RS Oncology LLC
Malignant Pleural Effusion, Malignant Pleural Mesothelioma, Mesothelioma, Mesotheliomas Pleural, Mesothelioma; Lung, Pleural Effusion, Malignant
04/25
04/25
TRACERx, NCT01888601: TRAcking Non-small Cell Lung Cancer Evolution Through Therapy (Rx)

Active, not recruiting
N/A
814
Europe
University College, London, Cancer Research UK
Non-small Cell Lung Cancer
12/26
12/26
Scotland, Molly
MiST, NCT03654833 / 2017-003353-41: Mesothelioma Stratified Therapy () : A Multi-drug Phase II Trial in Malignant Mesothelioma

Active, not recruiting
2
186
Europe
Rucaparib, CO-338, Abemaciclib, LY2835219, pembrolizumab & bemcentinib, Keytruda; BGB324, Atezolizumab & Bevacizumab, MPDL3280A; Avastin, Dostarlimab and Niraparib, Zejula
University of Leicester, British Lung Foundation, Clovis Oncology, Inc., Eli Lilly and Company, Merck Sharp & Dohme LLC, BerGenBio ASA, Roche Pharma AG, University Hospitals, Leicester, The Christie NHS Foundation Trust, GlaxoSmithKline
Mesothelioma, Malignant
10/23
10/23
MITOPE, NCT05278975: Study of RSO-021 in Patients With Malignant Pleural Effusion Due to Advanced/Metastatic Solid Tumors Including Mesothelioma

Recruiting
1/2
186
Europe
RSO-021, Thiostrepton
RS Oncology LLC
Malignant Pleural Effusion, Malignant Pleural Mesothelioma, Mesothelioma, Mesotheliomas Pleural, Mesothelioma; Lung, Pleural Effusion, Malignant
04/25
04/25

Download Options